Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : U.S. allows AstraZeneca to resume COVID-19 vaccine trial

10/23/2020 | 02:39pm EST

Oct 23 (Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by U.S. regulators, the company said on Friday.

AstraZeneca's U.S. trial was paused on Sept. 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial. (Reporting by Munsif Vengattil and Carl O'Donnell; Editing by Anil D'Silva and Rosalba O'Brien)


© Reuters 2020
All news about ASTRAZENECA PLC
03:14pASTRAZENECA : U.S. COVID-19 vaccine trial results likely in late-Jan, says healt..
RE
03:12pPFIZER, BIONTECH'S COVID-19 VACCINE : What You Need to Know
DJ
02:34pASTRAZENECA : As coronavirus soars, U.S. cheers Britain's vaccine approval
RE
02:33pPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 5th Update
DJ
02:30pMODERNA : Canada review of Pfizer's coronavirus vaccine candidate should be done..
RE
01:59pUK approves Pfizer-BioNTech COVID-19 vaccine in world first
RE
01:03pPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 4th Update
DJ
11:05aHow the U.K. Beat the U.S. and Europe to a Covid-19 Vaccine
DJ
09:29aASTRAZENECA : Crestor to be divested to Grunenthal in Europe
AQ
09:10aNorth Korea-linked hackers targeted J&J, Novavax in hunt for COVID research
RE
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 33,4x
Yield 2020 3,55%
Capitalization 104 B 139 B -
EV / Sales 2020 4,43x
EV / Sales 2021 3,84x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,91 $
Last Close Price 79,37 $
Spread / Highest target 95,9%
Spread / Average Target 53,6%
Spread / Lowest Target -16,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.54%137 451
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415